Vasopressin Injection — Class II drug recall D-0507-2024
Terminated recall by American Regent, Inc., reported 2024-05-29, distributed nationwide. Subpotent product in addition to having out-of-specification results for impurities.
| Recall number | D-0507-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | American Regent, Inc., New Albany, OH, United States |
| Recall initiated | 2024-05-13 |
| Classified | 2024-05-21 |
| Reported by FDA | 2024-05-29 |
| Terminated | 2025-12-22 |
| Distributed | Nationwide (US) |
| Quantity | 2,352 vials |
| Reason classes | potency, specification failure |
| NDC | 00517-1020, 00517-1020-01, 00517-1020-25, 00517-1030, 00517-1030-01 |
| Lot numbers | 23061L1C0 |
| Expiration dates | 2025-01-31 |
Product
Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous Infusion, American Regent, Inc., Shirley, NY 11967, NDC 0517-1030-01
Reason for recall
Subpotent product in addition to having out-of-specification results for impurities.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0507-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.